The combination of FAP+ CAF and EPH receptor A2 (EphA2)+ targeting resulted in complete tumor remission, which suggests a crucial supplemental role of CAF-targeting strategies along with conventional cancer therapies. This evidence concerns the gene EPHA2 and neoplasm.